Helixmith Co., Ltd (KOSDAQ:084990)

Market Cap	333.38B +199.2%
Revenue (ttm)	2.60B -47.8%
Net Income	-434.92M
EPS	-9.45
Shares Out	46.05M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	222,966
Average Volume	399,447
Open	6,800.00
Previous Close	7,240.00
Day's Range	6,800.00 - 7,200.00
52-Week Range	2,710.00 - 9,960.00
Beta	n/a
RSI	35.48
Earnings Date	Apr 2, 2026

About Helixmith

Helixmith Co., Ltd, a biotechnology company, discovers and develops biopharmaceuticals for human diseases. The company has a pipeline of novel biologics and herbal therapeutics in the areas of cardiovascular disease, cancer, and immune disorder, with clinical studies ongoing in the United States, Korea, and China. Its flagship product is VM202, a DNA-based drug for cardiovascular and neurological diseases. The company's pipeline products include VM206, a therapeutic cancer vaccine targeting HER2/neu positive breast or ovarian cancer; and VM501,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 084990

Financial Performance

In 2025, Helixmith's revenue was 2.60 billion, a decrease of -47.77% compared to the previous year's 4.97 billion. Losses were -434.92 million, -97.19% less than in 2024.